199 related articles for article (PubMed ID: 36170615)
21. Liposomal Daunorubicin and Cytarabine, a Potential Therapy for Blastic Plasmacytoid Dendritic Cell Neoplasm.
Ashok Kumar P; Ombada M; Pemmasani G; Tambe A; Banki K; Gentile T
J Investig Med High Impact Case Rep; 2022; 10():23247096221127114. PubMed ID: 36341907
[TBL] [Abstract][Full Text] [Related]
22. Blastic plasmacytoid dendritic cell neoplasm: evolving insights in an aggressive hematopoietic malignancy with a predilection of skin involvement.
Gera S; Dekmezian MS; Duvic M; Tschen JA; Vega F; Cho-Vega JH
Am J Dermatopathol; 2014 Mar; 36(3):244-51. PubMed ID: 24247574
[TBL] [Abstract][Full Text] [Related]
23. Blastic plasmacytoid dendritic cell neoplasm: report of a case presenting with lung and central nervous system involvement and review of the literature.
Feng Z; Zhou J; Bentley G
J La State Med Soc; 2014; 166(1):2-9. PubMed ID: 25075501
[TBL] [Abstract][Full Text] [Related]
24. Blastic plasmacytoid dendritic cell neoplasm: clinical features in 90 patients.
Julia F; Petrella T; Beylot-Barry M; Bagot M; Lipsker D; Machet L; Joly P; Dereure O; Wetterwald M; d'Incan M; Grange F; Cornillon J; Tertian G; Maubec E; Saiag P; Barete S; Templier I; Aubin F; Dalle S
Br J Dermatol; 2013 Sep; 169(3):579-86. PubMed ID: 23646868
[TBL] [Abstract][Full Text] [Related]
25. Blastic plasmacytoid dendritic cell neoplasm: update on molecular biology, diagnosis, and therapy.
Riaz W; Zhang L; Horna P; Sokol L
Cancer Control; 2014 Oct; 21(4):279-89. PubMed ID: 25310209
[TBL] [Abstract][Full Text] [Related]
26. Treatment of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): focus on the use of tagraxofusp and clinical considerations.
Pemmaraju N; Madanat YF; Rizzieri D; Fazal S; Rampal R; Mannis G; Wang ES; Foran J; Lane AA
Leuk Lymphoma; 2024 May; 65(5):548-559. PubMed ID: 38391126
[TBL] [Abstract][Full Text] [Related]
27. A CD56- immunoblastoid variant of blastic plasmacytoid dendritic cell neoplasm.
Aran BM; Duran J; Whittemore D; Gru AA
J Cutan Pathol; 2024 Jan; 51(1):40-44. PubMed ID: 37612885
[TBL] [Abstract][Full Text] [Related]
28. An analysis of blastic plasmacytoid dendritic cell neoplasm with translocations involving the MYC locus identifies t(6;8)(p21;q24) as a recurrent cytogenetic abnormality.
Sumarriva Lezama L; Chisholm KM; Carneal E; Nagy A; Cascio MJ; Yan J; Chang CC; Cherry A; George TI; Ohgami RS
Histopathology; 2018 Nov; 73(5):767-776. PubMed ID: 29884995
[TBL] [Abstract][Full Text] [Related]
29. Frontline Hyper-CVAD Plus Venetoclax for Pediatric Blastic Plasmacytoid Dendritic Cell Neoplasm.
He J; Garcia MB; Connors JS; Nuñez CA; Quesada AE; Gibson A; Roth M; Cuglievan B; Pemmaraju N; McCall D
J Pediatr Hematol Oncol; 2023 Nov; 45(8):e1001-e1004. PubMed ID: 37661300
[TBL] [Abstract][Full Text] [Related]
30. Social Media and Internet Resources for Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN).
Pemmaraju N; Gupta V; Thompson MA; Lane AA
Curr Hematol Malig Rep; 2016 Dec; 11(6):462-467. PubMed ID: 27492117
[TBL] [Abstract][Full Text] [Related]
31. Blastic plasmacytoid dendritic cell neoplasm (BPDCN): A promising future in the era of targeted therapeutics.
Adimora IJ; Wilson NR; Pemmaraju N
Cancer; 2022 Aug; 128(16):3019-3026. PubMed ID: 35726525
[TBL] [Abstract][Full Text] [Related]
32. Pediatric blastic plasmacytoid dendritic cell neoplasm: report of four cases and review of literature.
Liao C; Hu NX; Song H; Zhang JY; Shen DY; Xu XJ; Tang YM
Int J Hematol; 2021 May; 113(5):751-759. PubMed ID: 33392975
[TBL] [Abstract][Full Text] [Related]
33. Multicenter analysis of outcomes in blastic plasmacytoid dendritic cell neoplasm offers a pretargeted therapy benchmark.
Taylor J; Haddadin M; Upadhyay VA; Grussie E; Mehta-Shah N; Brunner AM; Louissaint A; Lovitch SB; Dogan A; Fathi AT; Stone RM; Tallman MS; Rampal RK; Neuberg DS; Stevenson KE; Horwitz SM; Lane AA
Blood; 2019 Aug; 134(8):678-687. PubMed ID: 31243042
[TBL] [Abstract][Full Text] [Related]
34. [Blastic plasmacytoid dendritic cell neoplasm variant acute leukemia: case report].
Flores-Angulo C; Chona Z; Sánchez MA; Salazar M; Hennig H
Rev Peru Med Exp Salud Publica; 2019; 36(2):353-359. PubMed ID: 31460652
[TBL] [Abstract][Full Text] [Related]
35. Features of non-activation dendritic state and immune deficiency in blastic plasmacytoid dendritic cell neoplasm (BPDCN).
Beird HC; Khan M; Wang F; Alfayez M; Cai T; Zhao L; Khoury J; Futreal PA; Konopleva M; Pemmaraju N
Blood Cancer J; 2019 Dec; 9(12):99. PubMed ID: 31811114
[TBL] [Abstract][Full Text] [Related]
36. Blastic Plasmacytoid Dendritic Cell Neoplasm-Current Insights.
Venugopal S; Zhou S; El Jamal SM; Lane AA; Mascarenhas J
Clin Lymphoma Myeloma Leuk; 2019 Sep; 19(9):545-554. PubMed ID: 31281107
[TBL] [Abstract][Full Text] [Related]
37. Blastic plasmacytoid dendritic cell neoplasm with a history of cytopenia: A case report.
Yan M; Wang W; Cen X; Wang L; Sun Y; Wang B; Ou J; Nong L; Ren H; Zhu P; Wang M
Diagn Cytopathol; 2020 Nov; 48(11):1102-1106. PubMed ID: 32374950
[TBL] [Abstract][Full Text] [Related]
38. [Enhancer hijacking via disease-specific chromosomal translocation in blastic plasmacytoid dendritic cell neoplasm].
Kubota S
Rinsho Ketsueki; 2020; 61(1):47-51. PubMed ID: 32023603
[TBL] [Abstract][Full Text] [Related]
39. Blastic plasmacytoid dendritic cell neoplasm: emerging developments and special considerations for 2023.
Pemmaraju N; Kantarjian H
Clin Adv Hematol Oncol; 2023 May; 21(5):257-264. PubMed ID: 37145496
[TBL] [Abstract][Full Text] [Related]
40. Blastic plasmacytoid dendritic-cell neoplasia: a challenging case report.
Koerber RM; Held SAE; Vonnahme M; Feldmann G; Wenzel J; Gütgemann I; Brossart P; Heine A
J Cancer Res Clin Oncol; 2022 Mar; 148(3):743-748. PubMed ID: 34529129
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]